{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:03:50Z","timestamp":1740146630134,"version":"3.37.3"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010983","name":"Health Research Fund of Central Denmark Region","doi-asserted-by":"publisher","award":["TECH-2014-627"],"award-info":[{"award-number":["TECH-2014-627"]}],"id":[{"id":"10.13039\/501100010983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008361","name":"Scleroseforeningen","doi-asserted-by":"crossref","award":["R34-A255-B143; R62-A619-B143; R89-A1581-B143; R367-A25613-B143; R431-A29821-B143"],"award-info":[{"award-number":["R34-A255-B143; R62-A619-B143; R89-A1581-B143; R367-A25613-B143; R431-A29821-B143"]}],"id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0223647","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T14:47:08Z","timestamp":1570718828000},"page":"e0223647","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inhaled nebulized glatiramer acetate against Gram-negative bacteria is not associated with adverse pulmonary reactions in healthy, young adult female pigs"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2602-197X","authenticated-orcid":true,"given":"Sandra M.","family":"Skovdal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig Hill","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Singers","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Viborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Henrik","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Jensen-Fangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Elisabeth","family":"Holm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vorup-Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eskild","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"issue":"2","key":"pone.0223647.ref001","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14787210.2018.1425139","article-title":"Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward \u2018molecularly targeted\u2019 therapy","volume":"16","author":"NG El Chakhtoura","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7154","key":"pone.0223647.ref002","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/448645a","article-title":"New uses for old drugs","volume":"448","author":"CR Chong","year":"2007","journal-title":"Nature"},{"issue":"11","key":"pone.0223647.ref003","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1021\/acsinfecdis.5b00100","article-title":"Investigational Agents for the Treatment of Gram-Negative Bacterial Infections: A Reality Check","volume":"1","author":"K Bush","year":"2015","journal-title":"ACS Infect Dis"},{"issue":"1","key":"pone.0223647.ref004","doi-asserted-by":"crossref","first-page":"15653","DOI":"10.1038\/s41598-017-15969-3","article-title":"The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria","volume":"7","author":"SH Christiansen","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"pone.0223647.ref005","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"KP Johnson","year":"1995","journal-title":"Neurology"},{"issue":"6","key":"pone.0223647.ref006","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/14737175.2015.1040768","article-title":"Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis","volume":"15","author":"AL Boster","year":"2015","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"pone.0223647.ref007","first-page":"247","article-title":"Long-term safety and tolerability of glatiramer acetate 20 mg\/ml in the treatment of relapsing forms of multiple sclerosis","volume":"16","author":"T Ziemssen","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"pone.0223647.ref008","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029249","article-title":"The Evolving Mechanisms of Action of Glatiramer Acetate","volume":"9","author":"T Prod\u2019homme","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"pone.0223647.ref009","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bbamem.2017.01.001","article-title":"The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage","volume":"1859","author":"SH Christiansen","year":"2017","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"6","key":"pone.0223647.ref010","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14712598.2017.1315402","article-title":"An overview of antimicrobial peptides and the latest advances in their development","volume":"17","author":"JM Sierra","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"pone.0223647.ref011","unstructured":"Retsinformation.dk. Bekendtg\u00f8relse af lov om dyrefors\u00f8g1) [Internet]. LBK nr 474 May 15, 2014. [cited 2019 May 2]. Available from: https:\/\/www.retsinformation.dk\/Forms\/R0710.aspx?id=%20162938."},{"key":"pone.0223647.ref012","unstructured":"European Commission. Legislation for the protection of animals used for scientific purposes\u2014Environment [Internet]. [cited 2019 Feb 28]. Available from: http:\/\/ec.europa.eu\/environment\/chemicals\/lab_animals\/legislation_en.htm"},{"issue":"1","key":"pone.0223647.ref013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1183\/20734735.021414","article-title":"Optimising inhaled mannitol for cystic fibrosis in an adult population","volume":"11","author":"PA Flume","year":"2015","journal-title":"Breathe Sheff Engl"},{"issue":"6","key":"pone.0223647.ref014","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"DJ Schuirmann","year":"1987","journal-title":"J Pharmacokinet BiopharmDec"},{"issue":"14","key":"pone.0223647.ref015","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1177\/1352458516688956","article-title":"Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results","volume":"23","author":"K Selmaj","year":"2017","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"5","key":"pone.0223647.ref016","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.autrev.2012.09.005","article-title":"The mechanism of action of glatiramer acetate in multiple sclerosis and beyond","volume":"12","author":"R Aharoni","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"11","key":"pone.0223647.ref017","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1164\/ajrccm.165.11.165111","article-title":"Volume of airway surface liquid in health and disease","volume":"165","author":"JH Widdicombe","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0223647.ref018","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jns.2017.03.030","article-title":"Two decades of glatiramer acetate: From initial discovery to the current development of generics","volume":"376","author":"B Weinstock-Guttman","year":"2017","journal-title":"J Neurol Sci"},{"issue":"20","key":"pone.0223647.ref019","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2174\/0929867321666140217110155","article-title":"Antimicrobial peptides: promising compounds against pathogenic microorganisms","volume":"21","author":"J Cruz","year":"2014","journal-title":"Curr Med Chem"},{"issue":"1","key":"pone.0223647.ref020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17425255.2017.1230200","article-title":"Colistin: still a lifesaver for the 21st century?","volume":"13","author":"I Karaiskos","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"pone.0223647.ref021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mib.2016.05.016","article-title":"Anti-biofilm peptides as a new weapon in antimicrobial warfare","volume":"33","author":"D Pletzer","year":"2016","journal-title":"Curr Opin Microbiol"},{"issue":"6","key":"pone.0223647.ref022","doi-asserted-by":"crossref","first-page":"e1007084","DOI":"10.1371\/journal.ppat.1007084","article-title":"Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens","volume":"14","author":"D Pletzer","year":"2018","journal-title":"PLoS Pathog"},{"key":"pone.0223647.ref023","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S1569-1993(19)30419-9","article-title":"P125 The multiple sclerosis drug, glatiramer acetate, acts as a resistance breaker with antibiotics from different classes against cystic fibrosis strains of Pseudomonas aeruginosa","volume":"18","author":"RA Murphy","year":"2019","journal-title":"J Cyst Fibros"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0223647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:54:02Z","timestamp":1588964042000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0223647"}},"subtitle":[],"editor":[{"given":"Monica","family":"Cartelle Gestal","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0223647","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,10,10]]}}}